Background: Artesunate has recently been used in some pharmacological preparation to induce tumor cell apoptosis. The drug is a semi-synthetic derivative of artemisinin, traditionally used for its antimalarial. However, up to now, its anticancer mechanism against diff erent types of tumors is not known.
Background
Cancer is one of the most leading causes of human death, worldwide, and breast cancer is the most common type of malignancy in women (1) . In Iran, breast cancer ranks the fi rst among cancers diagnosed in females with an increasing trend in the breast cancer related mortality rate in the recent decade (2) . The growth and survival of cancer cells is correlated with a reduced level of genetically programmed cell death; the apoptosis (3). Therefore, cytotoxic agents which induce apoptosis in the cancer cells are used as anticancer chemotherapeutic agents (4) . Therefore, all of the conventional therapies including chemotherapy, radiation, and hormonal treatments rely heavily on apoptosis for destroying breast cancer cells (5, 6) .
Apoptosis is characterized by both morphological and biochemical changes. The most important biochemical event during an early apoptosis is translocation of the phosphatidylserine from the inner to the outer cell membrane. In addition, there are various biochemical pathways during apoptosis which fi nally converge and result in the activation of a family of cysteine proteases called caspases (cysteine aspartate-specifi c proteases) (7) . Although, apoptosis can be mediated through caspase-dependent or caspase-independent pathways, the latter is the common mechanism, since most cells Jamalzadeh L et al. undergo apoptosis through the involvement of caspases.
Therefore, caspase pathways are considered as suitable candidate targets for anticancer drug discovery. It has been reported that some commonly used plant-derived anticancer drugs such as tamoxifen, doxorubicin, etoposide and cisplatin promote apoptosis in tumor cells through caspase pathways (8, 9) . Despite signifi cant pharmacological advances in treating breast cancer, it still remains an incurable disease for most patients, therefore, the quest to discover new treatments must continue (10) . In addition, there are several undesirable side eff ects associated with many of the present breast cancer chemotherapeutic agents (11) . One major challenge to overcome this problem is to develop the potent compounds with specifi city on the tumor cells but without the harmful side eff ects on normal mammalian cells (12) .
Natural products, especially plants' products, have been used for treating cancers for over 3,500 years. As an important natural source of new anticancer drugs with the minimal side eff ects (13) (14) (15) , several of such natural products still play an important role in the modern medicine. Plant secondary metabolites have proven to be excellent resources of new medications for cancer treatment (16) , as evidenced by eff ective plantderived anticancer agents including taxol and etoposide (17, 18) . Sesquiterpene lactones (SLs), a subfamily of terpenoids, are a group of plants' secondary metabolites which often are used in the traditional medicine for cancer treatment. These compounds are among the promising candidates in cancer drug discovery (19) .
Artemisinin is a sesquiterpene lactone isolated in 1972 from the Chinese medicinal herb, Artemisia annua L., used for treating fever and malaria for over two millennia (20, 21) . Although, artemisinin is one of the very few drugs used as antimalarials with minimal side eff ects (22) , it has pharmacokinetic limitations such as low solubility, a short half-life, as well as poor bioavilability (23) . Thus, in eff orts to overcome some of these problems, several semi-synthetic derivatives have designed and developed (12) . Besides their antimalarial activity, artemisinin and its derivatives have also shown to have signifi cant antitumor activity (24, 25) , antimicrobial (26) , antioxidant (27) , and anti-infl ammatory activity (28, 29) . Research on the anticancer properties of artemisisnin and its derivatives were started by the studies of Lai and Singh in 2004 when for the fi rst time, they showed that artemisinin induces apoptosis in human cancer cells and inhibits tumor growth (30) . In the recent years, there are many reports regarding the potent and broad anticancer activities of the artemisinin and its licensed semisynthetic derivatives in cell lines (30) (31) (32) , animal models (33) , and in clinical trials (19, 34) against various types of tumors including breast cancer. Considerable research has been focused on the most active water soluble semisynthetic derivative, artesunate. Analysing 55 human cancer cell lines, the Developmental Therapeutic Program of the NCI (National Cancer Institute) has shown that artesunate displays anticancer activity against diff erent cancerous cell lines (35) . In addition, it has been proven that artesunate exerts its anticancer activity through induction of apoptosis in the breast cancer cells (36) . On the other hand, because of its wide application as an anti-malarial drug with few side eff ects and excellent clinical safety (37) , there is growing evidence supporting the use of artesunate in cancer therapy (30) (31) (32) (33) (34) (35) 38) .
Although, it is currently in phase I-II clinical trials against breast, colorectal and non-small-cell lung cancers, the real potential and benefi ts of the artesunate for cancer treatment remains yet to be elucidated and the rationale for its use in anticancer therapy must be evaluated following to a deeper understanding of the underlying mechanisms involved in its cytotoxic eff ects (12) . However, despite the profound cytotoxic action of the artesunate against a wide spectrum of tumor cells, its anticancer signaling mechanism is still unclear (39) . Furthermore, the mechanisms by which artesunate and other artemisinin derivatives induce apoptosis, as well as the role of caspases to such eff ect, are not well understood. Therefore, further investigation is required in this fi eld. Due to the ability of artesunate to employ a variety of as yet undefi ned mechanisms for inducing apoptosis in the breast cancer cells, it might be useful to explore the exact mechanism that it plays in the breast tumors. The present study was designed to elucidate the anticancer activity of the most potent derivative of artemisinin, artesunate, on human breast cancer MCF-7 cells through determining the cytotoxicity and apoptosis induction by fl ow cytometry. This would, then, lead us to investigate the mechanism involved in the artesunate-induced apoptosis of MCF-7 cells based on the assessment of caspase activity.
Objective
The aim of this study was to determine if artesunate could induce apoptosis in human breast cancer cell line MCF-7 cells, and to explore the apoptotic signaling pathway underlying it. The possible mechanism of action of artesunate in breast cancer cells was explored by focusing on its ability to induce apoptosis as well as activation of the key apoptosis enzymes, caspases.
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Materials and Methods

Chemicals
All culture media including DMEM (Dulbecco's Modifi ed Eagle Medium)/F12 medium, trypsin-EDTA, penicillin-streptomycin solution and fetal bovine serum were obtained from Gibco (Invitrogen, South America). Trypan blue, 3-(4, 5 dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide (MTT) and artesunate powders were supplied from Sigma-Aldrich, USA. All chemicals, unless otherwise indicated, were purchased from Merck, Germany. In addition, annexin V-Fluorescein Isothiocyanate(FITC)/Propidium Iodide(PI) kit as well as Caspase-3, -8, -9 colorimetric assay kits were obtained from Abnova, Germany.
Cell Culture
Human breast cancer cell line, MCF-7, was purchased from the Iranian Biological Resource Center (IBRC™, Tehran, Iran) and cultured in DMEM/F12 medium supplemented with 10% FBS and 1% penicillin/ streptomycin. MCF-7 cells were incubated at 37 °C in a humidifi ed atmosphere of 5% CO 2 throughout the study and were routinely grown in 25 cm 2 culture fl asks. In order to harvest, cells were trypsinized after reaching to the growth confl uence, followed by centrifugation (1300 ×g for 7 min), and re-suspension in the culture medium. Cells in the log-phase of the growth were used for the following study.
Cytotoxicity Test-MTT Assay
To evaluate the cytotoxic eff ect of artesunate on the MCF-7 cells, MTT colorimetric assay was applied (40, 41) . Briefl y, MCF-7 cells at a density of approximately 1 × 10 4 cells per well were seeded into 96-well plates. Stock solutions of artesunate were prepared in acetone with a fi nal vehicle concentration that did not exceed 0.1% (vol/vol) for preparing diff erent concentrations of the artesunate (1, 5, 10, 25, 50, 75, 100, and 200 μg.mL -1 ). MCF-7 cells were treated for 24, 48, and 72h and 10 μL of MTT (5 mg.mL -1 ) was then added to each well and the plate was further incubated. After 4h, the supernatant in each well was carefully removed and 100 μL of DMSO (Dimethyl sulfoxide) was added in order to dissolve the resulting formazan crystals, the amount of which could be quantifi ed by determining absorbance at 570 nm using an ELISA (Enzyme-Linked Immunosorbent Assay) microplate reader (BioTek, USA). Then, the IC 50 value (inhibitory concentration; a concentration of a compound inhibiting 50% of the cell growth) was calculated and compared to that of the untreated control group.
Assessment of the Morphological Changes
The untreated MCF-7 cells (2×10 5 ) or cells treated with artesunate at a concentration of 25 μg.mL -1 for 24 h, were observed under an inverted microscope (Nikon, Japan).
Detection of Apoptosis by Flow Cytometry
Apoptosis was assessed by fl ow cytometry using an annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. Briefl y, MCF-7 cells (5 × 10 5 ) were treated with artesunate solution prepared to the fi nal concentrations of 5, 25, 50, 75, and 100 μg.mL -1 . After 24 h cells were gently trypsinized, washed once with serum-containing the medium and re-suspended in 500 μL of 1X binding buff er. Then, 5 μL of annexin V-FITC and 5 μL of propidium iodide (50 μg.mL -1 ) were added. After incubation at room temperature for 15 min in the dark, annexin V-FITC binding and propidium iodide staining were analyzed by fl ow cytometer (BD Falcon, USA) using the FITC signal detector (FL1) and phycoerythrin emission signal detector (FL2). Annexin V apoptosis detection assay is based on the key feature of apoptotic cells, which is translocation of phosphatidylserine (PS) from the inner leafl ets of the plasma membrane to the cell surface where it can be detected by labeling with a fl uorescent conjugate of annexin V, a Ca 2+ -dependent phospholipid-binding protein with a high affi nity for the phosohatidylserin. This assay can distinguish apoptosis and necrosis when performing both annexin V-FITC and PI staining since PI would detect necrotic cells with permeabilized plasma membrane.
Measurement of Caspase-3, -8, and -9 Activities
Caspase activation is a common apoptotic mechanism by which anticancer agents induce apoptosis. Thus, the level of caspase activation was determined to further elucidate the artesunate's mode of action. For this purpose, the cultivated MCF-7 cells (1 × 10 6 ) in 25 cm 2 fl asks were treated with 5, 25, 50, and 100 μg.mL -1 artesunate for 24 h or with a fi xed dose of 25 μg.mL -1 for 0, 4, 8, 12, 18, and 24 h. The activities of caspase-3, -8, and -9 were determined by using caspase colorimetric assay kits according to the manufacturer's recommended protocol. Briefl y, cells were washed with ice-cold PBS and lysed with 50 μL of chilled cell lysis buff er and incubated on ice for 10 minutes. After centrifuging for 1 min in a Microcentrifuge (10,000 ×g), the supernatant (cytosolic extract) was transferred to a fresh tube and put on ice for immediate assay. Protein concentrations of the supernatants were assessed by the Bradford method and 200 μg protein was then diluted to 50 μL cell lysis buff er for each assay. In addition, 50 μL of 2X reaction buff er (containing 10 mM DTT) and 4 mM DEVD-pNA substrate were added to each sample. After incubation at 37 °C for 2 h, samples were read at 405 nm using an ELISA microplate reader (BioTek, USA). The change in caspases' activities involved in the apoptosis) 3, 8, and 9) were determined by comparing these results with the level of the uninduced control.
Statistical Analysis
Each concentration was assayed in triplicates (n=3) and repeated in three independent experiments. SPSS statistical software (version 23.0, SPSS) was used for statistical analysis and values with p<0.05 were considered as statistically signifi cant. The results were analyzed using one-way ANOVA followed by Dunnett's test to compare groups with the control and were expressed as mean±SD. (Fig. 1). 
Results
Eff ects of Artesunate on MCF-7 Cell Proliferation
Eff ects of Artesunate on MCF-7 Cell Viability
Applying inverted microscopy, our observations show that artesunate inhibits proliferation of MCF-7 cells since there was a signifi cant diff erence in the cell viability between the treated and control cells. Following to exposure to artesunate, MCF-7 cells became round, small, and then were detached from the fl ask (Fig. 2). 
Eff ects of Artesunate on MCF-7 Cells Apoptosis
Annexin V/PI staining and fl ow cytometry were used to evaluate whether artesunate could induce cell death in MCF-7 cells via apoptosis. Flow cytometry analysis has positivity indicated that after treatment with artesunate at concentrations of 0 (as control), 5, 25, 50, and 100 μg.mL -1 for 24 h, cellular apoptosis rate increases by a concentration dependent manner to the certain concentrations, above which artesunate acts as a cytotoxic agent. The rate of induced apoptosis was according to the following order: 1.05 ± 0.21, 8.07 ± 0.13, 15.49 ± 1.46, 0.37 ± 0.33, and 3.31±0.51 for 0 to 100 μg.mL -1 of artesunate, respectively ( Fig.   3 . A to E). Thus, the apoptotic cell population has increased in a dose-dependent manner, peaking at 25 μg.mL -1 of artesunate and reaching a signifi cant diff erence to the control at 5 μg.mL -1 of the artesunate (p<0.05). Although, there was no diff erence between the artesunate of 50 and 100 μg.mL -1 compared to the control, however, cell death yet was increased as explained above (P>0.05).
Eff ects of Artesunate on the Activity of Caspase-3, -8 and -9
In most cases, diff erent anticancer agents eventually mediate a common apoptotic pathway through the Detection of early and late apoptosis by fl ow cytometry assay through annexin V and PI staining. MCF-7 cells were exposed to 5, 25, 50, and 100 μg.mL -1 of the artesunate for 24 h and then were subjected to the assessment by fl ow cytometry, (B-E, respectively). Also, MCF-7 cells were treated with medium only without artesunate as a control. Control (A).
activation of caspases (42) . In order to study the involvement of caspases in artesunate-induced apoptosis, activation of important key caspases (caspase-3, -8 and -9) in apoptotic pathways were investigated in MCF-7 cells upon exposure to the diff erent concentrations of artesunate (5-200 μg.mL -1 ) for 24h. In addition, in order to evaluate the time course of caspase activation, cells were treated with a fi xed concentration of 25 μg.mL -1 for the number of incubation time sets (i.e., 4, 8, 12, 18 , and 24 h). Enzyme assay indicated that the activities of caspase-8 and -9 in the artesunate treated MCF-7 cells were increased signifi cantly in a dose-and timedependent manner. However, exposure to 25 μg.mL -1 artesunate displayed the largest increase in the activity of both caspase-8 and -9 (Figs. 4A and B) . Interestingly, a brisk increase in the activity of caspase-8 was observed after 8h exposure to the eff ective dose of artesunate (25 μg.mL -1 ) which was decreased thereafter. A Similar result was obtained in case of caspase-9 but after 12 h (Figs. 5A and B) . Furthermore, treatment of the cells with 25 μg.mL -1 artesunate also activated the caspase-3, but to a lesser extent and in the diff erent doses and times, such that a prominent increase in the level of activation of eff ector caspase-3 was observed at 50 μg.mL -1 (Fig.  4 C) and after 24 h of exposure to the artesunate (Fig.  5C ).
Discussion
Breast cancer is the leading caus e of cancer death (1) which despite numerous treatment options including the conventional therapies, radiation, and surgery, still remains an incurable disease and a signifi cant public health problem (10) . Therefore, it is of high importance ) for 24 h. Each value is the mean ± SD of the three experiments. * Indicates a signifi cant diff erence between the untreated and artesunate-treated cells, p<0.05.
to search new eff ective drugs with specifi city on cancers but little or no side eff ects on normal mammalian cells.
Fortunately, artesunate is one among such few drugs. Widely used as an antimalarial drug, it doesn't show any signifi cant side eff ects and more importantly, its cytotoxic eff ect is specifi c to cancer cells (32) . Previous studies have demonstrated the profound antiproliferative activity of artesunate in diff erent cancer cell lines (35) including breast cancer cells as well as various types of animal cancer models (33, 38) In addition, several cases of signifi cant improvement in the breast cancer treatment after receiving artesunate have been reported (34) .
Despite the many recent reports of the potent anticancer activity of artesunate, both in vitro and in vivo, and even in the clinical trials against diff erent tumors, its molecular mechanism of action toward cancer cells (39) and apoptosis induction is still unexplored (43) . Also, to the best of our knowledge, there are no further reports on its mechanism of action in MCF-7 cells. Therefore, in the present study, we investigated the mechanism by which artesunate induced cell death in human breast cancer MCF-7 cell line.
The possible mechanism of action of artesunate in breast cancer cells was explored by focusing on its ability to induce apoptosis as well as activation of the key apoptosis enzymes, caspases. Our results showed that artesunate exerted a cytotoxic eff ect on MCF-7 cell line and inhibited the proliferation of the cells in a doseand time-dependent manner. Inverted microscopic observation also showed that fl oating cells increased in the breast cancer cells' culture treated with artesunate, suggesting that artesunate has inhibited the growth of MCF-7 cells. In addition, according to the result of fl ow cytometry, artesunate can induce apoptosis such that in doses lower than IC 50 (i.e. 5 and 25 μg.mL -1 ) mainly induced apoptosis, while at doses upper than IC 50 (i.e. 50 and 100 μg.mL -1 ) it is toxic toward the cells, increased the rate of cell death but not apoptosis. These fi ndings, which suggest apoptosis induction in the breast cancer cells, are consistent with the several other studies demonstrating in vitro anticancer activity of artesunate (44) (45) (46) .
However, there are limited reports regarding the mechanisms of artesunate-induced cell death in MCF-7 cells. On the other hand, apoptosis can be mediated through caspase-dependent or caspase-independent pathways. Thus, caspase activation was assessed to further elucidate the artesunate's mode of action in breast cancer cells. Caspases are the key regulatory proteins in apoptosis, which, based on their order in apoptotic pathways, could be classifi ed into two groups. These are initiator caspases (e.g. caspase-8 and -9) which mediate extrinsic and intrinsic apoptotic pathways, respectively, and eff ector caspases (e.g. caspase-3, -6 and -7) which are shared by the both apoptotic pathways following to the activation.
Among the eff ector caspases, caspase-3 is absolutely crucial for induction of apoptosis as by cleaving the majority of caspase substrates, this enzyme contributes to the typical morphological as well as biochemical changes associated with the apoptosis (47). Our results from caspase assay showed that activity of the caspases-3, -8, and -9 increased up to 25 μg.mL -1 of the artesunate and then it decreases upon application of higher concentrations. Moreover, the eff ect of artesunate on the level of caspase activation through the course of time and timing of apoptosis was diff erent. It was observed that artesunate exposure initiated the extrinsic pathway of the apoptosis with a brisk increase in levels of activated caspase-8 at 8 h followed by activation of caspase-9 at 12 h. Moreover, a prominent increase in the levels of eff ector caspase-3 was evident after 24 h of the artesunate exposure. These fi ndings clearly follow the established order of caspase activation cascade in caspase-dependent pathway in which upon activation, caspasae-8 initiates the mitochondrial pathway to apoptosis resulting in activation of caspase-9, and activated caspase-9 then instigates a caspase activation cascade by processing caspases-3 which propagates further caspase processing events, as depicted (48) . Thus, it seems that artesunate induces apoptosis in MCF-7 cells through both intrinsic and extrinsic caspase-dependent pathways and, therefore, exerts its anticancer eff ect.
The results of this study may provide evidence of the benefi cial eff ect of artesunate in the treatment of the breast tumors since it increases apoptosis in breast cancer cells. Also, considering the long-term administration of this drug as anti-malaria and its excellent safety profi le as well as outstanding cases of breast cancer treatment success, it could be concluded that artesunate may be a promising candidate as a cytotoxic chemotherapeutic agent for the treatment of breast cancer that can improve treatment options for these currently incurable diseases.
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